Shionogi Acquires Day One Biopharmaceuticals
Ticker: DAWN · Form: 8-K · Filed: May 30, 2024 · CIK: 1845337
Sentiment: neutral
Topics: acquisition, merger, biotech
TL;DR
Shionogi just bought Day One Bio. Deal closed May 29th.
AI Summary
On May 29, 2024, Day One Biopharmaceuticals, Inc. announced the completion of its acquisition by Shionogi & Co., Ltd. The transaction was completed following the satisfaction of customary closing conditions. Day One Biopharmaceuticals, Inc. was incorporated in Delaware and its principal executive offices are located in Brisbane, California.
Why It Matters
This acquisition signifies a significant consolidation in the biopharmaceutical sector, potentially impacting the development and availability of new cancer therapies.
Risk Assessment
Risk Level: low — The filing reports the completion of a previously announced acquisition, which is a standard corporate event.
Key Players & Entities
- Day One Biopharmaceuticals, Inc. (company) — Acquired company
- Shionogi & Co., Ltd. (company) — Acquiring company
- May 29, 2024 (date) — Date of acquisition completion
- Delaware (jurisdiction) — State of incorporation for Day One Biopharmaceuticals
- Brisbane, California (location) — Location of Day One Biopharmaceuticals' principal executive offices
FAQ
What was the primary event reported in this 8-K filing?
The primary event reported is the completion of the acquisition of Day One Biopharmaceuticals, Inc. by Shionogi & Co., Ltd.
When did the acquisition of Day One Biopharmaceuticals, Inc. officially close?
The acquisition officially closed on May 29, 2024.
Who is the acquiring company?
Shionogi & Co., Ltd. is the acquiring company.
Where were Day One Biopharmaceuticals, Inc.'s principal executive offices located?
Day One Biopharmaceuticals, Inc.'s principal executive offices were located at 2000 Sierra Point Parkway, Suite 501, Brisbane, California.
What is the Standard Industrial Classification (SIC) code for Day One Biopharmaceuticals, Inc.?
The Standard Industrial Classification (SIC) code for Day One Biopharmaceuticals, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 851 words · 3 min read · ~3 pages · Grade level 9.5 · Accepted 2024-05-30 08:35:47
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share DAWN Nasdaq Global Select
- $108.0 m — ase Priority Review Voucher ("PRV") for $108.0 million, payable in cash, upon the closin
- $8.1 million — Agreement. As part of the transaction, $8.1 million of the total consideration received fro
Filing Documents
- d834662d8k.htm (8-K) — 29KB
- d834662dex991.htm (EX-99.1) — 8KB
- d834662dex992.htm (EX-99.2) — 50KB
- g834662ex99_2p10g1.jpg (GRAPHIC) — 268KB
- g834662ex99_2p11g1.jpg (GRAPHIC) — 237KB
- g834662ex99_2p12g1.jpg (GRAPHIC) — 248KB
- g834662ex99_2p13g1.jpg (GRAPHIC) — 468KB
- g834662ex99_2p14g1.jpg (GRAPHIC) — 203KB
- g834662ex99_2p15g1.jpg (GRAPHIC) — 240KB
- g834662ex99_2p16g1.jpg (GRAPHIC) — 243KB
- g834662ex99_2p17g1.jpg (GRAPHIC) — 244KB
- g834662ex99_2p18g1.jpg (GRAPHIC) — 225KB
- g834662ex99_2p19g1.jpg (GRAPHIC) — 229KB
- g834662ex99_2p1g1.jpg (GRAPHIC) — 270KB
- g834662ex99_2p20g1.jpg (GRAPHIC) — 292KB
- g834662ex99_2p21g1.jpg (GRAPHIC) — 234KB
- g834662ex99_2p22g1.jpg (GRAPHIC) — 389KB
- g834662ex99_2p23g1.jpg (GRAPHIC) — 336KB
- g834662ex99_2p24g1.jpg (GRAPHIC) — 273KB
- g834662ex99_2p25g1.jpg (GRAPHIC) — 59KB
- g834662ex99_2p26g1.jpg (GRAPHIC) — 277KB
- g834662ex99_2p27g1.jpg (GRAPHIC) — 293KB
- g834662ex99_2p28g1.jpg (GRAPHIC) — 370KB
- g834662ex99_2p29g1.jpg (GRAPHIC) — 257KB
- g834662ex99_2p2g1.jpg (GRAPHIC) — 469KB
- g834662ex99_2p30g1.jpg (GRAPHIC) — 322KB
- g834662ex99_2p31g1.jpg (GRAPHIC) — 319KB
- g834662ex99_2p32g1.jpg (GRAPHIC) — 231KB
- g834662ex99_2p33g1.jpg (GRAPHIC) — 318KB
- g834662ex99_2p34g1.jpg (GRAPHIC) — 249KB
- g834662ex99_2p35g1.jpg (GRAPHIC) — 239KB
- g834662ex99_2p36g1.jpg (GRAPHIC) — 248KB
- g834662ex99_2p37g1.jpg (GRAPHIC) — 296KB
- g834662ex99_2p38g1.jpg (GRAPHIC) — 319KB
- g834662ex99_2p3g1.jpg (GRAPHIC) — 357KB
- g834662ex99_2p4g1.jpg (GRAPHIC) — 219KB
- g834662ex99_2p5g1.jpg (GRAPHIC) — 260KB
- g834662ex99_2p6g1.jpg (GRAPHIC) — 211KB
- g834662ex99_2p7g1.jpg (GRAPHIC) — 382KB
- g834662ex99_2p8g1.jpg (GRAPHIC) — 263KB
- g834662ex99_2p9g1.jpg (GRAPHIC) — 367KB
- g834662g66y20.gif (GRAPHIC) — 6KB
- 0001193125-24-149895.txt ( ) — 15015KB
- dawn-20240529.xsd (EX-101.SCH) — 3KB
- dawn-20240529_lab.xml (EX-101.LAB) — 18KB
- dawn-20240529_pre.xml (EX-101.PRE) — 11KB
- d834662d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release. 99.2 Corporate Presentation. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. DAY ONE BIOPHARMACEUTICALS, INC. Date: May 30, 2024 By: /s/ Charles N. York II, M.B.A. Charles N. York II, M.B.A. Chief Operating Officer and Chief Financial Officer